141108-78-3

Basic information

• Product Name: Boc-D-Serine Benzylamide
• Synonyms: Boc-D-Serine Benzylamide
• CAS NO: 141108-78-3
• Molecular Formula: C₁₅H₂₂N₂O₄
• Molecular Weight: 294.34618
• Mol File: 141108-78-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Boc-D-Serine Benzylamide(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-D-Serine Benzylamide(141108-78-3)
• EPA Substance Registry System: Boc-D-Serine Benzylamide(141108-78-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 141108-78-3(Hazardous Substances Data)

Usage

Uses

Boc-D-Serine Benzylamide is an intermediate for the preparation of lacosamide from enantiomerically pure D-serine derivative.

Upstream product

• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 100-46-9 benzylamine 

Downstream Products

• 32331-52-5 N-benzyl glyoxylic amide 
• 175481-31-9 N-Benzyl-L-serinamide 
• 158976-19-3 Boc-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NHCH₂C₆H₅ 
• 158976-17-1 Boc-Tyr-Pro-Ser-NHCH₂C₆H₅ 

Relevant articles and documents

Thiazolidin-5-imine Formation as a Catalyst-Free Bioorthogonal Reaction for Protein and Live Cell Labeling

A previously undescribed reaction involving the formation of a thiazolidin-5-imine linkage was developed for bioconjugation. Being highly specific and operating in aqueous media, this simple condensation reaction is used to chemoselectively label peptides, proteins, and living cells under physiological conditions without the need to use toxic catalysts or reducing reagents.

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted ω-phenyl-ω-(3-pyridyl)alkenoic acid derivatives and related compounds

A novel series of oxazolecarboxamide-substituted ω-phenyl-ω-(3- pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA2 receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4- [4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept- 6-enoic acid (14) with K(d) = 9.9 ± 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 ± 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, 'shunt' effect to elevate PGI2 level, and absence of agonist activity.